Overview
Germany life sciences supplier's Q1 revenue grew 7.5% in constant currencies, driven by consumables
Adjusted EBITDA margin was largely flat at 29.7%
Company confirmed full-year 2026 guidance, expects stronger second half
Outlook
Sartorius confirms 2026 group sales revenue growth of 5% to 9% in constant currencies
Company expects 2026 underlying EBITDA margin slightly above 30%
Management anticipates second half of 2026 to be stronger than first half
Result Drivers
CONSUMABLES DEMAND - Co said recurring consumables and services sales drove Q1 revenue growth in both of its divisions
TARIFFS AND MIX - Tariff impacts and product mix effects partly offset volume gains, affecting margins in both divisions
MATTEK ACQUISITION - MATTEK contributed to sales growth in Lab Products & Services division
Company press release: ID:nEQhYXb0a
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Slight Miss*
EUR 899.10 mln
EUR 899.61 mln (2 Analysts)
Q1 Net Income
EUR 56.20 mln
Q1 Adjusted EBITDA
EUR 267.30 mln
Q1 Adjusted EBITDA Margin
29.70%
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Sartorius AG is €265.50, about 43% above its April 22 closing price of €185.60
The stock recently traded at 31 times the next 12-month earnings vs. a P/E of 32 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)